ETF Holdings Breakdown of APLS

Stock NameApellis Pharmaceuticals Inc
TickerAPLS(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS03753U1060
LEI254900HS0ZFRXXSB9D42

News associated with APLS

Apellis Pharmaceuticals (NASDAQ:APLS) Hits New 52-Week Low Following Weak Earnings
Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) hit a new 52-week low during trading on Wednesday following a weaker than expected earnings announcement. The stock traded as low as $16.65 and last traded at $18.78, with a volume of 490307 shares. The stock had previously closed at $19.12. The company reported ($0.74) […] - 2025-05-08 06:08:52
Legal & General Group Plc Sells 10,879 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Legal & General Group Plc decreased its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 11.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 86,771 shares of the company’s stock after selling 10,879 shares during the quarter. Legal & General Group Plc […] - 2025-04-24 08:18:56
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Down 4.9% After Analyst Downgrade
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) shares fell 4.9% during mid-day trading on Tuesday after Royal Bank of Canada lowered their price target on the stock from $24.00 to $21.00. Royal Bank of Canada currently has a sector perform rating on the stock. Apellis Pharmaceuticals traded as low as $17.52 and last traded […] - 2025-04-24 05:15:10
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $21.00 at Royal Bank of Canada
Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its target price trimmed by Royal Bank of Canada from $24.00 to $21.00 in a report issued on Monday morning,Benzinga reports. The brokerage currently has a sector perform rating on the stock. Several other analysts have also commented on APLS. JPMorgan Chase & Co. lifted their price objective […] - 2025-04-22 05:54:45
Cerity Partners LLC Boosts Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Cerity Partners LLC lifted its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 48.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 46,667 shares of the company’s stock after acquiring an additional 15,286 shares during […] - 2025-04-18 09:24:57
Bank of Montreal Can Raises Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Bank of Montreal Can lifted its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 105.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 80,991 shares of the company’s stock after buying an additional 41,635 shares during the […] - 2025-04-17 08:42:51
KLP Kapitalforvaltning AS Takes $504,000 Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
KLP Kapitalforvaltning AS bought a new stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 15,800 shares of the company’s stock, valued at approximately $504,000. Several other hedge funds also […] - 2025-04-04 07:51:09
Prudential Financial Inc. Sells 89,700 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Prudential Financial Inc. trimmed its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 31.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 198,060 shares of the company’s stock after selling 89,700 shares during the period. Prudential Financial Inc. owned approximately 0.16% of Apellis […] - 2025-03-31 08:22:45
Signaturefd LLC Purchases 918 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Signaturefd LLC increased its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 357.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,175 shares of the company’s stock after acquiring an additional 918 shares during the quarter. Signaturefd LLC’s holdings in Apellis […] - 2025-03-26 07:48:50
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Rating of “Moderate Buy” from Analysts
Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) have been assigned an average rating of “Moderate Buy” from the nineteen research firms that are presently covering the firm, MarketBeat.com reports. Eight analysts have rated the stock with a hold recommendation, ten have issued a buy recommendation and one has given a strong buy […] - 2025-03-06 08:26:27
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Apellis Pharmaceuticals (NASDAQ:APLS) Stock
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) had its price target lifted by research analysts at JPMorgan Chase & Co. from $50.00 to $54.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would suggest a […] - 2025-03-06 08:26:26
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $29.00 at Wedbush
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) had its price objective reduced by equities research analysts at Wedbush from $30.00 to $29.00 in a research note issued to investors on Monday,Benzinga reports. The firm presently has a “neutral” rating on the stock. Wedbush’s price objective would indicate a potential upside of 15.77% from the stock’s […] - 2025-03-05 06:44:52
Apellis Pharmaceuticals (NASDAQ:APLS) Given “Buy” Rating at HC Wainwright
HC Wainwright restated their buy rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) in a research note published on Monday,Benzinga reports. HC Wainwright currently has a $57.00 price objective on the stock. A number of other brokerages have also commented on APLS. Citigroup dropped their price objective on shares of Apellis Pharmaceuticals from […] - 2025-03-04 06:50:55
Analyzing Apellis Pharmaceuticals (NASDAQ:APLS) & Aprea Therapeutics (NASDAQ:APRE)
Aprea Therapeutics (NASDAQ:APRE – Get Free Report) and Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation. Profitability This table compares Aprea Therapeutics and Apellis […] - 2025-02-26 06:23:06
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Short Interest Update
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) was the target of a large decline in short interest in January. As of January 31st, there was short interest totalling 17,060,000 shares, a decline of 5.4% from the January 15th total of 18,040,000 shares. Based on an average daily trading volume, of 2,640,000 shares, the short-interest […] - 2025-02-19 08:46:10

APLS institutional holdings

The following institutional investment holdings of APLS have been identified

Date ETF ISIN/Name Num Shares Book value
2025-05-08 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 50,315USD 896,110
2025-05-08 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 9,029USD 160,806
2025-05-08 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 59,839USD 1,065,733
2025-05-08 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 59,839USD 1,065,733 -1.0%
2025-05-08 IE000NITTFF2 (iShares Russell 1000 Growth UCITS ETF) 975USD 17,365 -1.0%
2025-05-08 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 221USD 3,936
Total =180,218 USD 3,209,683
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.